We also identified Rituximab-resistant, lymphoma B cells that overexpress CYCLON, without concomitant MYC deregulation, thus pointing to the existence of other as yet un-identified routes to CYCLON overexpression in lymphoma. Here, MYC is linked to lymphoma.